What were the key takeaways from Nyxoah’s earnings call?

What is Nyxoah's gross profit margin?

What is Nyxoah's latest dividend and current dividend yield?

Did Nyxoah beat or miss consensus estimates last quarter?

What is the market's earnings forecast for Nyxoah next quarter?

What is the revenue and EPS growth rate for Nyxoah year over year?

What guidance did Nyxoah's management provide for the next earnings period?

What factors drove the changes in Nyxoah's revenue and profit?

- **U.S. Launch Success**: 15 implants completed in first 7 weeks post-FDA approval, exceeding internal expectations.
- **Reimbursement Breakthrough**: 100% prior authorization approval rate, 35 VAC approvals secured.
- **Financial Strength**: EUR 26 million capital raise provides 18-month cash runway.
- **Gross Margin Path**: 80%+ achievable with Genio 2.2 launch in 2027.
- **Patient Impact**: 50-54 year-old patients driving early adoption, no CCC contraindication.

**【CEO Summary Section】**
- **U.S. Launch Momentum**: 15 implants completed across 9 accounts by end of October 2025, generating EUR 231,000 in revenue.
- **Surgeon Training Progress**: 111 surgeons trained on Genio, with 125 targeted accounts activated out of 400 high-volume sites.
- **Reimbursement Milestones**: 35 VAC approvals and 21 prior authorization submissions approved at 100% success rate.
- **Commercial Expansion**: 26 million EUR raised through private placement and convertible bonds, providing cash runway into Q1 2027.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q3 2025 revenue EUR 2 million (56% YoY growth), driven by U.S. launch and international expansion.
- **Financial Health**: Operating loss EUR 24.4 million (76% YoY increase) due to commercialization investments.
- **Gross Margin**: 60.5% (down 1.5% YoY) reflecting early-stage launch costs.
- **Q4 Guidance**: EUR 3.4-3.6 million revenue, with U.S. implants expected to accelerate post-VAC approvals.

**【Q&A Key Highlights】**
- **Implant Cadence**: 15 implants in September, ramping to 26 million EUR in Q4 2025.
- **Reimbursement Clarity**: CPT Code 64568 fully recognized by Medicare and 10 private payers.
- **Sales Force Scaling**: 85-person U.S. sales team targeting 400 high-volume implant sites by Q4 2026.
- **Gross Margin Outlook**: 80%+ achievable with Genio 2.2 launch in 2027.
- **Patient Demographics**: 50-54 year-old average age, no CCC contraindication in U.S. label.

Nyxoah SA (NYXH) Q3 2025 Earnings Call Transcript

- **FDA Milestone**: GENIOR becomes first bilateral AGNS therapy approved in the US, addressing unmet needs for CCC and positional OSA patients.
- **Revenue Surge**: Q2 2025 revenue up 73.8% YoY to €1.3M, driven by US launch investments.
- **Clinical Excellence**: DREAM study demonstrates 85.9% compliance and 90% patient satisfaction, validating real-world effectiveness.
- **Market Momentum**: 100+ trained physicians and VAC approvals secured within first week of commercialization.
- **Strategic Growth**: €27.5M debt facility and scalable sales team expansion support 2026 US market dominance.

**【CEO Opening Remarks】**
- **FDA PMA Approval Achieved**: GENIOR system approved for bilateral AGNS therapy in the US, first of its kind.
- **Differentiated Label Features**: No contraindication for CCC, ability to treat positional OSA (AHI score doubles in supine position).
- **Clinical Validation**: DREAM study published with 85.9% compliance and 90% patient satisfaction.
- **US Launch Momentum**: 50-person commercial team targeting 400 high-volume centers; 100+ physicians trained.
- **Reimbursement Strategy**: Using CPT code 64568, same as competitors, with CMS and payer engagement underway.

**【CFO Financial Update】**
- **Revenue Growth**: €1.3M (Q2 2025) vs. €0.8M (Q2 2024), +73.8% YoY.
- **Gross Margin**: 63.4%, stable vs. prior year.
- **Operating Loss**: €19.9M (Q2 2025) vs. €13.3M (Q2 2024), driven by US commercial investments.
- **Cash Position**: €43M (June 2025) with €27.5M debt facility available.

**【Q&A Highlights】**
- **Commercial Metrics Focus**: Trained physicians, VAC approvals, pre-authorization rates.
- **Reimbursement Timeline**: First pre-authorization approvals in Q2 2025, broader coverage in 2026.
- **CCC Patient Strategy**: ACCESS study enrollment stopped; PMA supplement submission expected in Q1 2026.
- **Sales Team Expansion**: Adding 15 territory managers annually to scale coverage.
- **Competitive Positioning**: Bilateral stimulation differentiation vs. unilateral competitors.


Nyxoah SA (NYXH) Q2 2025 Earnings Call Transcript

- **FDA Approval Imminent**: Final FDA inspection underway, Q2 2025 approval expected for Genio system.
- **U.S. Launch Readiness**: 50-person commercial team trained; leveraging proven CPT code 64568 and competitive pricing with unique patient-centric features.
- **Financial Resilience**: €63M cash runway extended to Q2 2026; Q1 revenue down 8% YoY due to market softness and software upgrade delays.
- **Clinical Differentiation**: Only AGNS with positional OSA data; no implanted battery, bilateral stimulation, and single incision procedure.
- **Middle East Momentum**: First AGNS implants in Dubai, expanding to Gulf states with strong clinical demand.

**【CEO Summary Section】**
- **FDA Approval Progress**: Received approvable letter for Genio system; final manufacturing validation completed and FDA site inspection ongoing, targeting Q2 2025 approval.
- **U.S. Market Strategy**: Two-pronged approach - targeting high-volume implant centers and sleep physicians with moderate-to-severe OSA patients. 50 commercial team members hired and trained.
- **Differentiation**: No implanted battery, bilateral stimulation, single incision procedure; clinical data shows effectiveness in positional OSA and supine sleep.
- **Reimbursement**: Utilizing established CPT code 64568, pricing similar to competitors with unique technology benefits.

**【CFO Financial Commentary】**
- **Q1 2025 Financials**: Revenue €1.1M (down 8% YoY) due to international market softness and Genio 2.1 software upgrade delays.
- **Operating Expenses**: €20.6M (up 69% YoY) driven by U.S. commercial team investments.
- **Cash Position**: €63M as of March 2025, with plans to extend cash runway into Q2 2026 through deferred spending.

**【Q&A Key Points】**
- **FDA Inspection Details**: Site inspection ongoing, expected to conclude shortly; no deficiencies noted in prior inspection.
- **Genio 2.1 Software**: Rolled out in U.S. without delays; provides gradual stimulation ramp-up and patient autonomy within physician-set boundaries.
- **Middle East Expansion**: First implants in Dubai, expanding to Kuwait and Saudi Arabia; AGNS first in the region.
- **Reimbursement Strategy**: Dedicated team for pre-authorization support, leveraging existing payer familiarity with CPT code 64568.
- **ACCCESS Study**: Enrolling patients for CCC indication, targeting 12-month data submission for PMA supplement.
- **Cost Management**: R&D expenses ~2024 levels; SG&A expected to double YoY, front-loaded in 2025.

Nyxoah SA (NYXH) Q1 2025 Earnings Call Transcript

- **FDA Approval Near**: Genio expected to receive U.S. FDA approval by end of March 2025, leveraging CPT code 64568 for competitive pricing.
- **Clinical Superiority**: DREAM study shows 82% super responders and 66.6% AHI reduction in supine sleep, outperforming competitors without supine data.
- **U.S. Market Play**: 50-person team targeting 300+ high-volume sites; 75+ trained physicians ready for launch.
- **Cash Position Strong**: €85.6M cash on hand, supporting Q4 2024 operating loss of €18.3M due to launch investments.
- **International Momentum**: UK NHS coverage and UAE first implant highlight expansion beyond Europe's 18% 2024 growth.

**【CEO Summary Section】**
- **Clinical Trial Success**: Genio achieved 63.5% AHI responder rate and 71.3% ODI responder rate in the DREAM study, with 82% of patients becoming super responders (AHI <15). Supine sleep efficacy showed 66.6% AHI reduction, outperforming competitors without supine data.
- **FDA Approval Imminent**: Final PMA module submitted in June 2024; FDA interactions focus on labeling, with expected approval by end of March 2025. Genio will use CPT code 64568, same as existing HGNS tech, enabling competitive pricing.
- **U.S. Launch Strategy**: 50-person commercial team to target 300-350 high-volume HGNS sites and build referral networks with sleep physicians. Already trained 75+ U.S. physicians through clinical trials.
- **International Expansion**: Launched in UK (NHS coverage) and UAE; Germany revenue grew 46% QoQ in Q4 2024, with full-year growth of 18%.

**【CFO Financial Commentary】**
- **Revenue Performance**: Q4 2024 revenue €1.3M (excluding €0.6M deferred patch revenue), full-year €4.5M. Deferred revenue recognized over time as patches are delivered.
- **Financial Position**: Cash balance €85.6M at year-end (up from €57.7M), supported by €24.6M equity raise. Operating loss €18.3M in Q4, driven by R&D, commercial, and U.S. launch investments.

**【Q&A Key Themes】**
- **Reimbursement Strategy**: CPT code 64568 adoption expected to align pricing with competitors, with CMS coverage from launch. Commercial payers anticipated to approve by Q3/Q4 2025.
- **Market Uptake**: Genio's bilateral stimulation and non-pacemaker form factor differentiate from existing HGNS. Early focus on 75+ trained physicians and high-volume sites, scaling to 300+ accounts over 12-18 months.
- **Supply Chain Readiness**: U.S.-manufactured inventory sufficient for launch; no global shipping delays expected.
- **Real-World Data**: Post-market studies to collect clinical and economic evidence, supporting long-term adoption.


NYXH

NYXH fundamentals

Earnings Call

You can ask Aime